Clinical Trial Update: A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase II study evaluating Abraxane (nab-paclitaxel) in combination with Nexavar (sorafenib) as first-line treatment for locally advanced or metastatic breast ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• Nexavar (Sorafenib)

Snippet

Sponsor: Veeda Oncology | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED